HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CF PHARMTECH

36.980

+0.2000.54%

Volume:239.00K

Turnover:8.79M

Market Cap:15.24B

PE:650.21

High:37.500

Open:37.000

Low:35.800

Close:36.780

52wk High:48.800

52wk Low:27.200

Shares:412.00M

HK Float Shares:302.22M

Volume Ratio:1.19

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(LYR):0.057

ROE:-5.62%

ROA:-5.30%

PB:13.99

PE(LYR):650.21

PS:22.21

Loading ...

Overview Company News Filings

BRIEF-CF Pharmtech Says NMPA Accepted IND Application For ICF004

CF PharmTech Says Chinese Regulators Accept Investigational New Drug Application for ICF004

MT Newswires Live

CF PharmTech (2652) Reports IND Acceptance for Inhaled Dry Powder Candidate ICF004

Bulletin Express

CF PHARMTECH's IND Application for ICF004 Accepted by NMPA

China’s NMPA Accepts CF PharmTech’s IND Application for ICF004

CF Pharmtech Inc - Nmpa Accepts Ind Application for ICF004

THOMSON REUTERS

CF PHARMTECH Spends HK$290,300 on Buyback of 8,000 Shares on February 20

CF PharmTech (02652.HK) Reports Share Repurchase and Issued Shares Update

Bulletin Express

CF PHARMTECH (02652) Allocates HK$290,300 for Share Buyback on February 20

CF PharmTech files HKEX next-day disclosure return for 8,000-share buyback at HK$36.2825 each

Hong Kong Stock Announcement Highlights: Insilico, Seyond, and CF Pharmtech Added to Hang Seng Composite Index Constituents

CF PharmTech, Inc. (02652) Announces Share Repurchase and Completes Next Day Disclosure Return

Bulletin Express

CF PHARMTECH Repurchases 73,000 Shares for HK$2.64 Million on February 16

CF Pharmtech Repurchases 73,000 Shares for HKD 2.64 Million in HKEX Filing

CF PharmTech, Inc. (2652) Included in Hang Seng Composite Index

Bulletin Express

CF PharmTech Inc. joins Hang Seng Composite Index

CF PHARMTECH (02652) Added to Hang Seng Composite Index, Poised for Southbound Trading Inclusion on March 9

CF PharmTech, Inc. (02652) Announces Share Repurchase and Updated Issued Shares

Bulletin Express

CF PHARMTECH (02652) Allocates HK$962,500 for Share Buyback on February 13

CF Pharmtech Repurchases 27,500 Shares for HKD 962,490 in HKEX Disclosure

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02652/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02652","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","market":"HK","secType":"STK","nameCN":"CF PHARMTECH","latestPrice":36.98,"timestamp":1771920487522,"preClose":36.78,"halted":0,"volume":239000,"delay":0,"changeRate":0.005437737901033054,"floatShares":302223586,"shares":412000000,"eps":0.056874,"marketStatus":"Closed","change":0.2,"latestTime":"02-24 16:08:07","open":37,"high":37.5,"low":35.8,"amount":8792630,"amplitude":0.046221,"askPrice":37.4,"askSize":1000,"bidPrice":36.98,"bidSize":6000,"shortable":0,"etf":0,"ttmEps":0.073,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771983000000},"marketStatusCode":5,"adr":0,"listingDate":1759852800000,"exchange":"SEHK","adjPreClose":36.78,"openAndCloseTimeList":[[1771896600000,1771905600000],[1771909200000,1771920000000]],"volumeRatio":1.192202,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","floatShares":302223586,"roa":"-5.30%","roe":"-5.62%","lyrEps":0.056874,"volumeRatio":1.192202,"shares":412000000,"dividePrice":0,"high":37.5,"amplitude":0.046221,"preClose":36.78,"low":35.8,"week52Low":27.2,"pbRate":"13.99","psRate":"22.21","week52High":48.8,"institutionHeld":0,"latestPrice":36.98,"committee":0.714286,"eps":0.056874,"divideRate":0,"volume":239000,"delay":0,"ttmEps":0.073,"open":37,"prevYearClose":35,"prevWeekClose":36,"prevMonthClose":36.4,"prevQuarterClose":35,"fiveDayClose":35.28,"twentyDayClose":34.68,"sixtyDayClose":35.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02652\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02652\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02652\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02652\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02652","date":"2026-02-23","current":506.575342,"percent":0.868132,"low":-293.764894,"twenty":409.242359,"median":455.282385,"eighty":477.290783,"high":513.213561,"avg":438.920487,"sd":84.757459,"marketCap":15139213933},"quantilePoints":[{"date":"2025-10-10","current":420.512992,"twenty":-8.053739,"median":420.512992,"eighty":438.465035,"marketCap":12738371726},{"date":"2025-10-17","current":400.969089,"twenty":380.917252,"median":393.18793,"eighty":412.695431,"marketCap":12136883281},{"date":"2025-10-24","current":382.04749,"twenty":383.954109,"median":395.798507,"eighty":407.879105,"marketCap":11568353106},{"date":"2025-10-31","current":411.638127,"twenty":385.87135,"median":395.798507,"eighty":410.009732,"marketCap":12482945126},{"date":"2025-11-07","current":380.629431,"twenty":385.87135,"median":397.412529,"eighty":410.009732,"marketCap":11535394836},{"date":"2025-11-14","current":413.442652,"twenty":386.82146,"median":399.24986,"eighty":411.625005,"marketCap":12565340803},{"date":"2025-11-21","current":474.663516,"twenty":387.596392,"median":401.654037,"eighty":419.1227,"marketCap":14419243545},{"date":"2025-11-28","current":513.213561,"twenty":390.697015,"median":408.734506,"eighty":451.19497,"marketCap":15646939138},{"date":"2025-12-05","current":509.365027,"twenty":391.797785,"median":411.605323,"eighty":487.699676,"marketCap":15556303893},{"date":"2025-12-12","current":478.26383,"twenty":394.588712,"median":413.442652,"eighty":485.541496,"marketCap":14633472306},{"date":"2025-12-19","current":468.273561,"twenty":396.041553,"median":429.606948,"eighty":482.974301,"marketCap":14361566570},{"date":"2025-12-24","current":469.497744,"twenty":396.770692,"median":439.211078,"eighty":482.563912,"marketCap":14443962248},{"date":"2026-01-02","current":452.984556,"twenty":397.492287,"median":451.385447,"eighty":481.570975,"marketCap":13990786022},{"date":"2026-01-09","current":417.797013,"twenty":398.674444,"median":438.955991,"eighty":480.057858,"marketCap":12936121351},{"date":"2026-01-16","current":442.060347,"twenty":399.985866,"median":432.778937,"eighty":478.730146,"marketCap":13731858722},{"date":"2026-01-23","current":466.639698,"twenty":400.772068,"median":439.902936,"eighty":477.371374,"marketCap":14481468286},{"date":"2026-01-30","current":480.840623,"twenty":401.791027,"median":446.916666,"eighty":477.757159,"marketCap":14990389486},{"date":"2026-02-06","current":464.022312,"twenty":403.190746,"median":452.185001,"eighty":477.033593,"marketCap":14502764350},{"date":"2026-02-13","current":452.173894,"twenty":406.744138,"median":454.320794,"eighty":475.6532,"marketCap":14213623359},{"date":"2026-02-20","current":472.094804,"twenty":408.734506,"median":454.916554,"eighty":476.776403,"marketCap":14818441932},{"date":"2026-02-23","current":481.94993,"twenty":409.242359,"median":455.282385,"eighty":477.290783,"marketCap":15139213933}],"updateTime":1771920435243},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02652\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613752470","title":"BRIEF-CF Pharmtech Says NMPA Accepted IND Application For ICF004","url":"https://stock-news.laohu8.com/highlight/detail?id=2613752470","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613752470?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:48","pubTimestamp":1771897730,"startTime":"0","endTime":"0","summary":"BRIEF-CF Pharmtech Says NMPA Accepted IND Application For ICF004Feb 24 (Reuters) - CF PharmTech Inc 2652.HK:NMPA ACCEPTS IND APPLICATION FOR ICF004Further company coverage: 2652.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZJ149:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"gpt_icon":0},{"id":"2613234752","title":"CF PharmTech Says Chinese Regulators Accept Investigational New Drug Application for ICF004","url":"https://stock-news.laohu8.com/highlight/detail?id=2613234752","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613234752?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:48","pubTimestamp":1771897690,"startTime":"0","endTime":"0","summary":"CF PharmTech (HKG:2652) said Chinese regulators had accepted its investigational new drug application to study ICF004 in clinical trials, according to a Hong Kong bourse filing Tuesday.The medicine is intended as a treatment for progressive fibrosing interstitial lung disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02652","BK4585","BK4588","BK1191","CF","BK4093"],"gpt_icon":0},{"id":"1196977848","title":"CF PharmTech (2652) Reports IND Acceptance for Inhaled Dry Powder Candidate ICF004","url":"https://stock-news.laohu8.com/highlight/detail?id=1196977848","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196977848?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:21","pubTimestamp":1771885291,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. (2652) announced that the investigational new drug application (IND) for ICF004, an inhaled dry powder candidate for treating progressive fibrosing interstitial lung disease, has...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"1113594511","title":"CF PHARMTECH's IND Application for ICF004 Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1113594511","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113594511?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:20","pubTimestamp":1771885223,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that the Investigational New Drug (IND) application for its self-developed candidate drug ICF004, an inhaled dry powder formulation, has been accepted by China's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK1191","02652"],"gpt_icon":0},{"id":"2613758730","title":"China’s NMPA Accepts CF PharmTech’s IND Application for ICF004","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758730","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758730?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:08","pubTimestamp":1771884512,"startTime":"0","endTime":"0","summary":"CF PharmTech Inc. said China’s National Medical Products Administration has accepted an investigational new drug application for ICF004, an internally developed inhaled dry powder candidate. The company said ICF004 is intended for the treatment of progressive fibrosing interstitial lung disease, including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, and noted that acceptance is an administrative step that does not constitute marketing approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 23, 2026, and is solely responsible for the inform","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL8kGb9W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"gpt_icon":0},{"id":"2613758784","title":"CF Pharmtech Inc - Nmpa Accepts Ind Application for ICF004","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758784?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:08","pubTimestamp":1771884495,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZJ149:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02652"],"gpt_icon":0},{"id":"1182171225","title":"CF PHARMTECH Spends HK$290,300 on Buyback of 8,000 Shares on February 20","url":"https://stock-news.laohu8.com/highlight/detail?id=1182171225","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182171225?lang=en_us&edition=fundamental","pubTime":"2026-02-22 13:00","pubTimestamp":1771736422,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that on February 20, 2026, the company repurchased 8,000 shares at a cost of HK$290,300.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"1144671424","title":"CF PharmTech (02652.HK) Reports Share Repurchase and Issued Shares Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1144671424","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144671424?lang=en_us&edition=fundamental","pubTime":"2026-02-20 18:23","pubTimestamp":1771582984,"startTime":"0","endTime":"0","summary":"CF PharmTech (02652.HK) disclosed that on 20 February 2026, it repurchased 8,000 shares on the Hong Kong Stock Exchange at an average price of HKD 36.28 per share. The highest repurchase price was...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"1128948128","title":"CF PHARMTECH (02652) Allocates HK$290,300 for Share Buyback on February 20","url":"https://stock-news.laohu8.com/highlight/detail?id=1128948128","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128948128?lang=en_us&edition=fundamental","pubTime":"2026-02-20 18:12","pubTimestamp":1771582330,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that on February 20, the company repurchased 8,000 shares at a total cost of HK$290,300.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"2612263061","title":"CF PharmTech files HKEX next-day disclosure return for 8,000-share buyback at HK$36.2825 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2612263061","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612263061?lang=en_us&edition=fundamental","pubTime":"2026-02-20 18:03","pubTimestamp":1771581811,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc.  filed a Next Day Disclosure Return with HKEX reporting an on-market share repurchase on 20 February 2026. The company repurchased 8,000 H shares at prices ranging from HK$36.08 to HK$36.50 per share , paying an aggregate HK$290,260, with the shares held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL7h9G4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"1157516521","title":"Hong Kong Stock Announcement Highlights: Insilico, Seyond, and CF Pharmtech Added to Hang Seng Composite Index Constituents","url":"https://stock-news.laohu8.com/highlight/detail?id=1157516521","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157516521?lang=en_us&edition=fundamental","pubTime":"2026-02-20 09:18","pubTimestamp":1771550300,"startTime":"0","endTime":"0","summary":"【Major Developments】Insilico (03696) has been added as a constituent of the Hang Seng Composite Index. Seyond (02665) has been added as a constituent of the Hang Seng Composite Index. CF Pharmtech...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","VT","03696","02498","BK1144","BK1589","BK1191","03692","HSCI","02652","02665","BK1179","BK4585","BK1141","VXUS","BK4588"],"gpt_icon":0},{"id":"1183438346","title":"CF PharmTech, Inc. (02652) Announces Share Repurchase and Completes Next Day Disclosure Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1183438346","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183438346?lang=en_us&edition=fundamental","pubTime":"2026-02-16 18:42","pubTimestamp":1771238534,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. (02652) issued a Next Day Disclosure Return dated 16 February 2026, outlining repurchase activity and the resulting changes in its share capital structure. On 16 February 2026, the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"1157217012","title":"CF PHARMTECH Repurchases 73,000 Shares for HK$2.64 Million on February 16","url":"https://stock-news.laohu8.com/highlight/detail?id=1157217012","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157217012?lang=en_us&edition=fundamental","pubTime":"2026-02-16 18:32","pubTimestamp":1771237930,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that on February 16, 2026, the company repurchased 73,000 of its own shares at a total cost of approximately HK$2.64 million.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"2611072841","title":"CF Pharmtech Repurchases 73,000 Shares for HKD 2.64 Million in HKEX Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2611072841","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611072841?lang=en_us&edition=fundamental","pubTime":"2026-02-16 18:26","pubTimestamp":1771237618,"startTime":"0","endTime":"0","summary":"CF PharmTech Inc. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 73,000 shares at a total price of HKD 2,637,170. The repurchased shares will be held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nNDLcbvfkr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"1197767199","title":"CF PharmTech, Inc. (2652) Included in Hang Seng Composite Index","url":"https://stock-news.laohu8.com/highlight/detail?id=1197767199","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197767199?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:42","pubTimestamp":1771216940,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. (2652) has announced that, following the quarterly review of the Hang Seng Family of Indexes for the period ended December 31, 2025, it will be included as a constituent stock of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"2611510802","title":"CF PharmTech Inc. joins Hang Seng Composite Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2611510802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611510802?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:33","pubTimestamp":1771216392,"startTime":"0","endTime":"0","summary":"CF PharmTech Inc. will be added as a constituent stock of the Hang Seng Composite Index, effective March 9, 2026. The inclusion reflects the capital market's recognition of the company's leading position in the respiratory disease treatment market and its capabilities in inhalation drug delivery technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nNDL4ZsvbS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"1134516820","title":"CF PHARMTECH (02652) Added to Hang Seng Composite Index, Poised for Southbound Trading Inclusion on March 9","url":"https://stock-news.laohu8.com/highlight/detail?id=1134516820","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134516820?lang=en_us&edition=fundamental","pubTime":"2026-02-16 11:12","pubTimestamp":1771211548,"startTime":"0","endTime":"0","summary":"On February 13, 2026, the Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series, based on data as of December 31, 2025. CF PHARMTECH (02652) was...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VT","02652","HSCI","BK4588","VXUS"],"gpt_icon":0},{"id":"1137682981","title":"CF PharmTech, Inc. (02652) Announces Share Repurchase and Updated Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1137682981","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137682981?lang=en_us&edition=fundamental","pubTime":"2026-02-13 19:01","pubTimestamp":1770980467,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. (02652) disclosed a repurchase of 27,500 ordinary H shares on 13 February 2026. The company indicates these repurchased shares, at an average price of HKD 34.9996 per share, have...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"1118614672","title":"CF PHARMTECH (02652) Allocates HK$962,500 for Share Buyback on February 13","url":"https://stock-news.laohu8.com/highlight/detail?id=1118614672","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118614672?lang=en_us&edition=fundamental","pubTime":"2026-02-13 18:46","pubTimestamp":1770979591,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that on February 13, 2026, the company repurchased 27,500 of its own shares at a total cost of HK$962,500.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0},{"id":"2611153273","title":"CF Pharmtech Repurchases 27,500 Shares for HKD 962,490 in HKEX Disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2611153273","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611153273?lang=en_us&edition=fundamental","pubTime":"2026-02-13 18:41","pubTimestamp":1770979267,"startTime":"0","endTime":"0","summary":"CF PharmTech Inc. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 27,500 shares at an aggregate price of HKD 962,490. The repurchased shares will be held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDLxVGvy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":87,"code":"91000000","status":"200"}]}}